Back to Search Start Over

Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group

Authors :
Giardino, S.
de Latour, R. P.
Aljurf, M.
Eikema, D. -J.
Bosman, P.
Bertrand, Y.
Tbakhi, A.
Holter, W.
Bornhauser, M.
Rossig, C.
Burkhardt, B.
Zecca, M.
Afanasyev, B.
Michel, G.
Ganser, A.
Alseraihy, A.
Ayas, M.
Uckan-Cetinkaya, D.
Bruno, B.
Patrick, K.
Bader, P.
Itala-Remes, M.
Rocha, V.
Jubert, C.
Diaz, M. A.
Shaw, P. J.
Junior, L. G. D.
Locatelli, Franco
Kroger, N.
Faraci, M.
Pierri, F.
Lanino, E.
Miano, M.
Risitano, A.
Robin, M.
Dufour, C.
Locatelli F. (ORCID:0000-0002-7976-3654)
Giardino, S.
de Latour, R. P.
Aljurf, M.
Eikema, D. -J.
Bosman, P.
Bertrand, Y.
Tbakhi, A.
Holter, W.
Bornhauser, M.
Rossig, C.
Burkhardt, B.
Zecca, M.
Afanasyev, B.
Michel, G.
Ganser, A.
Alseraihy, A.
Ayas, M.
Uckan-Cetinkaya, D.
Bruno, B.
Patrick, K.
Bader, P.
Itala-Remes, M.
Rocha, V.
Jubert, C.
Diaz, M. A.
Shaw, P. J.
Junior, L. G. D.
Locatelli, Franco
Kroger, N.
Faraci, M.
Pierri, F.
Lanino, E.
Miano, M.
Risitano, A.
Robin, M.
Dufour, C.
Locatelli F. (ORCID:0000-0002-7976-3654)
Publication Year :
2020

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative for bone marrow failure in patients with Fanconi anemia (FA), but the presence of a malignant transformation is associated with a poor prognosis and the management of these patients is still challenging. We analyzed outcome of 74 FA patients with a diagnosis of myelodysplastic syndrome (n = 35), acute leukemia (n = 35) or with cytogenetic abnormalities (n = 4), who underwent allo-HSCT from 1999 to 2016 in EBMT network. Type of diagnosis, pre-HSCT cytoreductive therapies and related toxicities, disease status pre-HSCT, donor type, and conditioning regimen were considered as main variables potentially influencing outcome. The 5-year OS and EFS were 42% (30-53%) and 39% (27-51%), respectively. Patients transplanted in CR showed better OS compared with those transplanted in presence of an active malignant disease (OS:71%[48-95] vs 37% [24-50],P =.04), while none of the other variables considered had an impact. Twenty-two patients received pre-HSCT cytoreduction and 9/22 showed a grade 3-4 toxicity, without any lethal event or negative influence on survival after HSCT(OS:toxicity pre-HSCT 48% [20-75%] vs no-toxicity 51% [25-78%],P =.98). The cumulative incidence of day-100 grade II-IV a-GvHD and of 5-year c-GvHD were 38% (26-50%) and 40% (28-52%). Non-relapse-related mortality and incidence of relapse at 5-years were 40% (29-52%) and 21% (11-30%) respectively, without any significant impact of the tested variables. Causes of death were transplant-related events in most patients (34 out of the 42 deaths, 81%). This analysis confirms the poor outcome of transformed FA patients and identifies the importance of achieving CR pre-HSCT, suggesting that, in a newly diagnosed transformed FA patient, a cytoreductive approach pre-HSCT should be considered if a donor have been secured.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1382658609
Document Type :
Electronic Resource